ZOLL Respicardia Announces SelectHealth Coverage for the remedē® System in Patients with Central Sleep Apnea
Expanded insurance coverage now available in Utah, Idaho and Nevada
September 20, 2022
Expanded insurance coverage now available in Utah, Idaho and Nevada
August 5, 2021
The new remedē EL-X model delivers extended longevity, reduced size, and an enhanced suite of diagnostics
May 17, 2021
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the peer-reviewed journal Nature and Science of Sleep has published five-year results from the remedē System Post Approval Study.
April 12, 2021
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA).
January 6, 2021
Expanded insurance coverage now available in Pennsylvania, Delaware and West Virginia